Archives: “Archives”

David B. Beck, MD, PhD

https://www.coltonconsortium.org/directory/david-b-beck-md-phd/

Associate Director, Judith & Stewart Colton Center for Autoimmunity, NYU Grossman School of Medicine / NYU Langone Health, New York University Assistant Professor, Department of Medicine, NYU Grossman School of […]

Edward Behrens, MD

https://www.coltonconsortium.org/directory/edward-behrens-md/

Joseph Hollander Chair in Pediatric Rheumatology, Children’s Hospital of Philadelphia Chief, Division of Rheumatology, Children’s Hospital of Philadelphia Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania Dr. […]

Scott Canna, MD

https://www.coltonconsortium.org/directory/scott-canna-md/

Associate Professor, Department of Pediatrics (Rheumatology), Children’s Hospital of Philadelphia / University of Pennsylvania Dr. Scott Canna is Associate Professor of Pediatrics in the Division of Rheumatology at the Children’s […]

Cornelius Y. Taabazuing, PhD

https://www.coltonconsortium.org/directory/cornelius-y-taabazuing-phd/

Presidential Assistant Professor, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania Dr. Cornelius Taabazuing is a Presidential Assistant Professor in the Department of Biochemistry and Biophysics […]

Development of UBA1 Targeted Therapies in VEXAS Syndrome

https://www.coltonconsortium.org/projects/development-of-uba1-targeted-therapies-in-vexas-syndrome/

Building a fluorescence-based cellular screening platform to identify small molecules targeting mutant UBA1, this project addresses an acute unmet need in VEXAS syndrome and lays groundwork for broader rheumatic disease therapies.

The Role and Mechanism of Aberrant Dendritic Cell Function in Autoimmunity

https://www.coltonconsortium.org/projects/the-role-and-mechanism-of-aberrant-dendritic-cell-function-in-autoimmunity/

Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.

Utilizing RNA Replicons as Immune Modulators for Systemic Lupus Erythematosus

https://www.coltonconsortium.org/projects/utilizing-rna-replicons-as-immune-modulators-for-systemic-lupus-erythematosus/

A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.

Inhibiting NETosis with Nuclear-Penetrating Antibodies

https://www.coltonconsortium.org/projects/inhibiting-netosis-with-nuclear-penetrating-antibodies/

Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.

Identifying Modifiers of Rhinovirus-Induced Pathological Inflammation to Combat Asthma

https://www.coltonconsortium.org/projects/identifying-modifiers-of-rhinovirus-induced-pathological-inflammation-to-combat-asthma/

Identifying the signaling pathways that drive rhinovirus-induced airway inflammation to find small molecule drugs that prevent asthma attacks.

Targeted Nanoparticles to Treat Inflammation After Intracerebral Hemorrhage

https://www.coltonconsortium.org/projects/targeted-nanoparticles-to-treat-inflammation-after-intracerebral-hemorrhage/

Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.